WESTMINSTER, Colo., November 18, 2025--(BUSINESS WIRE)--TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for ...
Hosted on MSN
TriSalus reaffirms 50% revenue growth target while advancing TriNav platform and product launches
CEO Mary Szela reported strong third quarter results, highlighting revenue of $11.6 million, a 57% increase year-over-year and 3% sequential growth. She noted continued expansion of the TriNav ...
TriSalus Life Sciences reported Q3 2025 revenue of $11.6M, up 57% YoY and 3% QoQ, driven by expanding adoption of its TriNav platform. Management reaffirmed 50% FY revenue growth guidance and ...
DENVER, November 07, 2024--(BUSINESS WIRE)--TriSalus Life Sciences ® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), a leader in oncology innovations integrating advanced delivery technology to ...
DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative ...
– Data published in Current Medical Research and Opinion provide a comparison of the TriNav Infusion System vs. standard drug delivery and show the ability of TriNav to successfully treat sicker, ...
(RTTNews) - TriSalus Life Sciences, Inc. (TLSI) has unveiled the TriNav FLX Infusion System, a new addition to its TriNav portfolio. The latest system enhances trackability and flexibility, allowing ...
DENVER & SALT LAKE CITY--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results